ARTV
Artiva Biotherapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$180.19M
P/E Ratio
—
EPS
$-3.43
Beta
—
52W High
$7.75
52W Low
$1.47
50-Day MA
$5.16
200-Day MA
$3.74
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc. is an innovative biotechnology company focused on developing next-generation cell therapies for cancer. Leveraging a proprietary platform to enhance natural killer (NK) cell therapies, Artiva is advancing an extensive pipeline targeting a variety of hematologic and solid tumors. The company's commitment to scientific excellence and strategic partnerships positions it as a key player in the dynamic field of immuno-oncology. As it moves forward with clinical development of its promising therapeutic candidates, Artiva aims to transform cancer treatment and significantly improve patient outcomes.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-87.21M |
| Operating Margin | 0.00% |
| Return on Equity | -56.60% |
| Return on Assets | -33.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.53 |
| Price-to-Book | 1.51 |
| Price-to-Sales (TTM) | 8.11 |
| EV/Revenue | 7.54 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $24.72M |
| Float | $4.23M |
| % Insiders | 27.71% |
| % Institutions | 68.83% |
Analyst Ratings
Consensus ($17.00 target)
1
Strong Buy5
BuyData last updated: 4/7/2026